Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, informs its shareholders that the ordinary shareholder meeting was held on May 16, 2017 and all resolutions were approved. The extraordinary shareholder meeting convened on first call could not be held as the quorum required by law was not reached.

The shareholders thus are convened on second call for an Extraordinary shareholder meeting on same agenda on Tuesday May 30, 2017 at 2:00 pm CET in the offices of Drakkar D – BuroClub – room Colomb – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.

The documents mentioned in articles R.225-73-1 of the French Code de commerce, including those to be presented at the shareholder meeting, are available on the Company’s website www.nicox.com. These documents are also available to shareholders at the headquarters of the Company.

Shareholders may vote by proxy, by internet or by attending the shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, is available on Nicox’s website. Shareholders may also contact the Company’s Investor Relations team at Age2017@nicox.com for any question on the voting process.

Renewal of the terms of office of Mrs. Birgit Stattin Norinder and Michele Garufi

Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced the appointment of Mrs. Lauren P. Silvernail to the Company’s Board of Directors, for a period of four years. Mrs. Silvernail brings to Nicox more than 30 years of experience in leading business growth and financial strategies for life science companies, including nine years at ISTA Pharmaceuticals, a commercial ophthalmic company that was acquired by Bausch + Lomb in 2012. Mrs. Silvernail currently serves as Chief Financial Officer and Chief Business Officer of Revance Therapeutics, Inc. where she led its 2014 initial public offering and has raised more than $450 million in capital since joining that company.

Today, Nicox also announced that Mrs. Birgit Stattin Norinder, already Board member of Nicox since 2011, has been re-elected by the Company’s shareholders as a Board member for a period of four years, as well as Michele Garufi to serve another four year term of office.

“Lauren’s operational experience in drug development and ophthalmology will complement Nicox’ Board of Directors and her deep knowledge of the global financial markets brings transactional expertise that is a welcome addition,” said Mr. Garufi, Chairman and Chief Executive Officer of Nicox. “As we prepare for the anticipated potential approvals of Vyzulta^TM1 and ZERVIATE² during Q3 2017, Lauren’s broad background provides us with valuable expertise as we look to grow and advance our business and expand our globally recognized R&D efforts in ophthalmology. We are delighted to add Lauren’s experience in the ophthalmology field and we look forward to her contribution as Nicox continues to grow.”

Mrs. Silvernail commented: “As a leading R&D company in ophthalmology, and with a rapidly advancing clinical and preclinical pipeline, Nicox is an exciting growth story. I look forward to joining the team to help develop the strategies that will further accelerate the Company’s growth.”

Prior to Revance Therapeutics, Inc., Mrs. Silvernail was Chief Financial Officer and Vice President of Corporate Development at ISTA Pharmaceuticals, Inc. where she was a key architect of the company’s growth and financing plans, securing over $275 million in financing for the company and culminating in the sale of ISTA to Bausch + Lomb in a $500 million cash transaction. Before that, Mrs. Silvernail served in various operating and corporate development positions for Allergan, most recently as Vice President of Business Development. While at Allergan, she led and closed acquisitions, licensing and co-promotion transactions. Earlier in her career, she was a general partner of a seed venture capital fund and led a start-up venture as its first Chief Executive Officer. Prior to that, Mrs. Silvernail served in marketing roles at Varian and Bio-Rad Laboratories. She holds an M.B.A. from the University of California, Los Angeles and a B.A. in Biophysics from the University of California at Berkeley.

Notes:

1. VyzultaTM is the provisionally approved tradename for latanoprostene bunod ophthalmic solution, 0.024%
2. ZERVIATE is the tradename provisionally approved for cetirizine ophthalmic solution, 0.24%